CN Patent

CN1674910A — 氮斯汀和甾族化合物的组合

Assigned to Cipla Ltd · Expires 2005-09-28 · 21y expired

What this patent protects

本发明涉及一种药物产品或制剂，其包含氮斯汀或其药学可接受的盐、溶剂化物或生理功能性衍生物，以及甾族化合物或其药学可接受的盐、溶剂化物或生理功能性衍生物，优选该产品或制剂为适于鼻内或眼内给药的形式。

USPTO Abstract

本发明涉及一种药物产品或制剂，其包含氮斯汀或其药学可接受的盐、溶剂化物或生理功能性衍生物，以及甾族化合物或其药学可接受的盐、溶剂化物或生理功能性衍生物，优选该产品或制剂为适于鼻内或眼内给药的形式。

Drugs covered by this patent

azelastine-hydrochloride (AZELASTINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN1674910A
Jurisdiction: CN
Classification: —
Expires: 2005-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Cipla Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.